4//SEC Filing
Heyman Richard A. 4
Accession 0001415889-24-025381
CIK 0001672619other
Filed
Oct 16, 8:00 PM ET
Accepted
Oct 17, 5:06 PM ET
Size
7.1 KB
Accession
0001415889-24-025381
Insider Transaction Report
Form 4
Heyman Richard A.
Director
Transactions
- Sale
Common Stock
2024-10-15$27.67/sh−1,270$35,143→ 124,490 total
Holdings
- 37,407(indirect: See footnote)
Common Stock
- 27,918(indirect: See footnote)
Common Stock
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023.
- [F2]This transaction was executed in multiple trades at prices ranging from $27.1521 to $27.9631. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]The shares are held of record by the Richard A. Heyman and Anne E. Daigle Trust, dated November 1, 2016 for which the Reporting Person serves as trustee.
- [F4]The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member.
Documents
Issuer
Enliven Therapeutics, Inc.
CIK 0001672619
Entity typeother
Related Parties
1- filerCIK 0001584759
Filing Metadata
- Form type
- 4
- Filed
- Oct 16, 8:00 PM ET
- Accepted
- Oct 17, 5:06 PM ET
- Size
- 7.1 KB